Stock Price, News, Quote and Profile of BIOGEN INC(NASDAQ:BIIB) stock

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

BIOGEN INC

NASDAQ:BIIB (7/26/2024, 7:19:04 PM)

After market: 211.17 0 (0%)

211.17

-16.27 (-7.15%)

Chartmill TA Rating

Chartmill Setup Rating

Sector

GICS SectorHealth Care

GICS IndustryBiotechnology

GICS SubIndustry

Chartmill FA Rating

Valuation

Growth

Profitability

Health

Dividend

Chartmill High Growth Momentum

EPS Q2Q%

Sales Q2Q%

CRS

6 Month-13.74%

Overview

Earnings (Last)

Earnings (Next)

Ins Owners

Inst Owners

Market Cap30.75B

PE13.76

Fwd PE11.91

Dividend YieldN/A

Analysts

IPO

Stock Screener Links

GICS Sector Stock Screener

Find competitors from the same sector on the USA

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

Company Profile

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 7,570 full-time employees. The company has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). The company is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. The Company’s marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS; and FUMADERM for the treatment of severe plaque psoriasis. The company also has collaborations for the commercialization of LEQEMBI, ZURZUVAE, RITUXAN, RITUXAN HYCELA, GAZYVA, OCREVUS, LUNSUMIO, and COLUMVI. The company commercializes a portfolio of biosimilars of advanced biologics including BENEPALI, IMRALDI, FLIXABI, and BYOOVIZ.

Company Info

BIOGEN INC

225 Binney Street

Cambridge MASSACHUSETTS 02142

P: 17814642000

CEO: Michel Vounatsos

Employees: 7570

Website: https://www.biogen.com/

BIIB News

7 hours ago - ChartmillCurious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session.

Stay informed about the performance of the S&P500 index one hour before the close of the markets on Friday. Uncover the top gainers and losers in today's session for valuable insights.

9 hours ago - ChartmillTop S&P500 movers in Friday's session

Let's have a look at what is happening on the US markets in the middle of the day on Friday. Below you can find the top S&P500 gainers and losers in today's session.